230 related articles for article (PubMed ID: 31695154)
21. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
22. KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.
Hershkovitz D; Vlodavsky E; Simon E; Ben-Izhak O
Pathol Int; 2013 Dec; 63(12):611-4. PubMed ID: 24422958
[TBL] [Abstract][Full Text] [Related]
23. Borderline Brenner Tumor of the Ovary Coexisting With an Ovarian Mucinous Cystadenoma With Focal Atypical Epithelial Proliferation: A Rare Case With Review of the Literature.
Salibay CJ; Zanfagnin V; Miller H; Walia S; Brunette LL; Wang T
Int J Surg Pathol; 2021 Oct; 29(7):788-793. PubMed ID: 33635096
[TBL] [Abstract][Full Text] [Related]
24. Matching maternal isodisomy in mucinous carcinomas and associated ovarian teratomas provides evidence of germ cell derivation for some mucinous ovarian tumors.
Kerr SE; Flotte AB; McFalls MJ; Vrana JA; Halling KC; Bell DA
Am J Surg Pathol; 2013 Aug; 37(8):1229-35. PubMed ID: 23774174
[TBL] [Abstract][Full Text] [Related]
25. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.
Ryland GL; Hunter SM; Doyle MA; Rowley SM; Christie M; Allan PE; Bowtell DD; ; Gorringe KL; Campbell IG
J Pathol; 2013 Feb; 229(3):469-76. PubMed ID: 23096461
[TBL] [Abstract][Full Text] [Related]
26. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
[TBL] [Abstract][Full Text] [Related]
27. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
[TBL] [Abstract][Full Text] [Related]
28. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.
Vang R; Gown AM; Zhao C; Barry TS; Isacson C; Richardson MS; Ronnett BM
Am J Surg Pathol; 2007 Jun; 31(6):854-69. PubMed ID: 17527072
[TBL] [Abstract][Full Text] [Related]
29. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
Werness BA; DiCioccio RA; Piver MS
Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
31. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
[TBL] [Abstract][Full Text] [Related]
32. Ovarian mucinous tumors arising from mature cystic teratomas--a molecular genetic approach for understanding the cellular origin.
Fujii K; Yamashita Y; Yamamoto T; Takahashi K; Hashimoto K; Miyata T; Kawai K; Kikkawa F; Toyokuni S; Nagasaka T
Hum Pathol; 2014 Apr; 45(4):717-24. PubMed ID: 24485845
[TBL] [Abstract][Full Text] [Related]
33. Methylation profile of imprinted genes provides evidence for teratomatous origin of a subset of mucinous ovarian tumours.
Kato N; Kamataki A; Kurotaki H
J Pathol; 2021 Aug; 254(5):567-574. PubMed ID: 33983633
[TBL] [Abstract][Full Text] [Related]
34. Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI; Killian JK; Venstrom JM; Ramkissoon SH; Ross JS; Elvin JA
Mod Pathol; 2021 May; 34(5):983-993. PubMed ID: 33077920
[TBL] [Abstract][Full Text] [Related]
35. Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma.
Taguchi A; Rokutan H; Oda K; Tanikawa M; Tanimoto S; Sone K; Mori M; Tsuruga T; Kohsaka S; Tatsuno K; Shinozaki-Ushiku A; Miyagawa K; Mano H; Aburatani H; Ushiku T; Osuga Y
BMC Med Genomics; 2022 Mar; 15(1):51. PubMed ID: 35255903
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins.
Wang Y; Schwartz LE; Anderson D; Lin MT; Haley L; Wu RC; Vang R; Shih IeM; Kurman RJ
Oncotarget; 2015 Sep; 6(26):22949-58. PubMed ID: 26355245
[TBL] [Abstract][Full Text] [Related]
39. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
40. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
